SABS PE Ratio & Valuation, Is SABS Overvalued

Historical Valuation

SAB Biotherapeutics Inc (SABS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -8.14. The fair price of SAB Biotherapeutics Inc (SABS) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 3.83 USD , SAB Biotherapeutics Inc By Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：3.83

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is SAB Biotherapeutics Inc (SABS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

SAB Biotherapeutics Inc (SABS) has a current Price-to-Book (P/B) ratio of 1.08. Compared to its 3-year average P/B ratio of 1.21, the current P/B ratio is approximately -10.49% higher. Relative to its 5-year average P/B ratio of 2.70, the current P/B ratio is about -59.80% higher. SAB Biotherapeutics Inc (SABS) has a Forward Free Cash Flow (FCF) yield of approximately -20.94%. Compared to its 3-year average FCF yield of -104.36%, the current FCF yield is approximately -79.93% lower. Relative to its 5-year average FCF yield of -74.14%, the current FCF yield is about -71.75% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SABS competitors is 812.38, providing a benchmark for relative valuation. SAB Biotherapeutics Inc Corp (SABS.O) exhibits a P/S ratio of 3230.05, which is 297.6% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SABS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SABS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SABS currently overvalued or undervalued?

What is SAB Biotherapeutics Inc (SABS) fair value?

SABS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of SAB Biotherapeutics Inc (SABS) is between +Inf to +Inf according to relative valuation method.

How does SABS's valuation metrics compare to the industry average?

The average P/S ratio for SABS's competitors is 812.38, providing a benchmark for relative valuation. SAB Biotherapeutics Inc Corp (SABS) exhibits a P/S ratio of 3230.05, which is 297.60% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for SAB Biotherapeutics Inc (SABS) as of Apr 01 2026?

As of Apr 01 2026, SAB Biotherapeutics Inc (SABS) has a P/B ratio of 1.08. This indicates that the market values SABS at 1.08 times its book value.

What is the current FCF Yield for SAB Biotherapeutics Inc (SABS) as of Apr 01 2026?

As of Apr 01 2026, SAB Biotherapeutics Inc (SABS) has a FCF Yield of -20.94%. This means that for every dollar of SAB Biotherapeutics Inc's market capitalization, the company generates -20.94 cents in free cash flow.

What is the current Forward P/E ratio for SAB Biotherapeutics Inc (SABS) as of Apr 01 2026?

As of Apr 01 2026, SAB Biotherapeutics Inc (SABS) has a Forward P/E ratio of -4.73. This means the market is willing to pay $-4.73 for every dollar of SAB Biotherapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for SAB Biotherapeutics Inc (SABS) as of Apr 01 2026?

As of Apr 01 2026, SAB Biotherapeutics Inc (SABS) has a Forward P/S ratio of 0.00. This means the market is valuing SABS at $0.00 for every dollar of expected revenue over the next 12 months.

SABS Valuation